Common TitleLESS
Official Title A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)
Phase Phase IIIB
ClinicalTrials.gov NCT00363142
Treatments
Fosamprenavir
Fosamprenavir
Tradename:LexivaOther Names:FPVClass:Protease Inhibitors (PI)Categories Treatment-Experienced
Funding
IndustryGlaxoSmithKline
References
- Cohen C, Dejesus E, Lamarca A, et al. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. HIV Clin Trials. 2010;11:239-47.